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Abstract. Anti-Pv200 antibody levels were assessed in samples from endemic areas of Plasmodium vivax malaria
in the Republic of Korea (ROK), using an indirect enzyme-linked immunosorbent assay (ELISA) method. Asymp-
tomatic carriers of P. vivax were detected using nested polymerase chain reaction (PCR) of blood samples. Anti-
Pv200 antibody levels in 20 vivax malaria patients (optical density  standard deviation [OD  SD] values 1.85 
0.29 of IgG isotype and 1.33  1.33 of IgM isotype) were markedly higher than those of uninfected, malaria-naive
controls (0.08  0.16 of IgG isotype and 0.04  0.04 of IgM isotype). Antibody levels for 7 out of 8 soldiers with
a recent malaria infection were sustained above the cut-off values for 4 months after successful treatment. Analysis
of serum collected from 40 healthy, asymptomatic soldiers who had a P. vivax malaria attack within 3 months after
our sampling, revealed 11 antibody-positive samples (27.5%), compared to 5 positive samples (12.5%) collected from
a random selection of 40 soldiers. Among a larger pool of 1,713 soldiers who had served in high-risk areas for P.
vivax transmission, 15% were antibody positive. Among 1,000 blood samples from asymptomatic soldiers who had
served in the high-risk areas, 4 samples (0.4%) were parasite positive, as determined by nested PCR. Our results
show that anti-Pv200 antibody levels can provide useful information in the late diagnosis of P. vivax malaria infection
in a previously naive population and also in large seroepidemiologic studies. Furthermore, our results suggest that
asymptomatic P. vivax carriers could be important in the current outbreak of malaria in Korea.
INTRODUCTION
Although previously known as an endemic area of Plas-
modium vivax, the Republic of Korea (ROK) had been con-
sidered free from malaria parasites because no reports of
autochthonous transmission had been documented since
1984. However, since re-emergence of a single case of P.
vivax malaria in 1993, the number of malaria cases has in-
creased exponentially in the northwestern part of the ROK
(northern Kyunggi Province), causing more than 1,700 cases
in 1997, and an estimated 4,000 cases in 1998.1–4 Histori-
cally, Korean P. vivax malaria has an atypically long incu-
bation period (lasting up to a year or longer) in a large pro-
portion of patients but a typically mild clinical course5—
characteristics which appear to apply to the current epidem-
ic. Serologic responses to malaria parasite infections in
Korea have not been reported previously, although serology
would be a logical approach to detect infection during the
long incubation period. The indirect enzyme-linked immu-
nosorbent assay (ELISA) has been developed to detect and
monitor antibodies against cell extracts, circumsporozoite
(CS) antigen, or merozoite surface protein 1 (MSP 1) of
Plasmodium spp.6–10 The indirect ELISA method could be a
simple, inexpensive approach for diagnosis of asymptomatic
carriers, as well as for the seroepidemiologic study of a large
number of populations.
In this study, we measured antibody levels against Pv200
antigen, the MSP 1 homolog in P. vivax (Sal I strain), and
against P. vivax CS protein by indirect ELISA of serum from
infected and uninfected ROK Army soldiers who had served
in high risk areas of P. vivax transmission. We also searched
for the presence of circulating P. vivax parasites by perform-
ing nested PCR on subjects’ blood. In this report, we dem-
onstrate that the anti-Pv200 antibody levels might provide
useful information in diagnosis and prognosis of the popu-
lation exposed to Korean P. vivax malaria, as well as in large
seroepidemiologic studies. We were also able to detect
asymptomatic P. vivax carriers by nested PCR.
MATERIALS AND METHODS
Subjects and sample collection. This study conducted by
the Korean Armed Forces Central Medical Research Institute
was approved and reviewed annually by the Research Re-
view Board in the ROK Armed Forces Medical Command.
All participating soldiers were informed of the study objec-
tives and on-going threats of Korean P. vivax malaria; sub-
jects provided written personal histories and signed informed
consent for their participation prior to sampling.
In late May 1997, samples for serum and whole blood
were collected by venipuncture from 1,000 randomly se-
lected Korean soldiers who had served in areas of northern
Kyunggi Province, Korea, with high risk of P. vivax trans-
mission during the summer of 1996. These soldiers were still
stationed in the P. vivax malaria-endemic areas at the time
of sampling in May 1997, but sometime after the autumn of
1996 they had left these high-risk malarious areas to other
service locations where the risk of P. vivax transmission was
much lower. According to the report by the ROK Armed
Forces Medical Command, 40 of the 1,000 soldiers sampled
in May 1997, were later diagnosed and treated for P. vivax
malaria. The emergence of these cases was within 3 months
after our sampling.
For the second round of our large seroepidemiological
survey, we collected serum from 1,713 Korean soldiers, be-
ginning in early January 1998, who had served in high-risk
areas of northern Kyunggi Province since the summer of
1997. Of these, 8 soldiers who had a previous history of P.
vivax malaria could be sampled twice more during the sub-
sequent 5 months.
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FIGURE 1. Anti-Pv200 antibody levels in a normal control group
determined by indirect enzyme-linked immunosorbent assay
(ELISA). The thick solid horizontal line and dotted horizontal line
represent the cut-off values of optical densities (OD) in anti-Pv200
IgG isotype (0.5) and IgM isotype (0.2) antibodies, respectively. The
thin horizontal lines indicate the mean OD in each anti-Pv200 an-
tibody titer.
Negative control sera from malaria-naive subjects were
collected from 113 soldiers in the Korean Armed Forces
Medical School and from 200 civilians (kindly provided by
the Korean Red Cross). None of the 313 subjects who do-
nated negative control sera had a previous history of malaria
or temporary residence in malaria-endemic areas.
Positive control sera were obtained from 20 malaria pa-
tients who had been admitted to ROK military field hospitals
of northern Kyunggi Province and had been confirmed by
examination of peripheral blood film smears during the sum-
mers of 1997 and 1998.
Indirect ELISA. The 19kDa fragment of Pv200, mero-
zoite surface protein 1 (MSP 1) of P. vivax (Sal I strain),
was expressed in the yeast Saccharomyces cerevisiae. The
expression, purification, and characterization of this antigen
have been described in detail elsewhere.9 V20, CS capture
antigen containing 20 tandem repeats of predominant, also
known as Pv210, nonapeptide (GDRAA/DGQPA) from P.
vivax CS protein, was kindly provided by Dr. Robert A.
Wirtz (Centers for Disease Control and Prevention).10 Titers
of antibodies against Pv200 and V20 were determined by an
indirect ELISA procedure with minor modifications from
Kaslow and others.9 and Wirtz and others.10 Briefly, 96-well
microtiter plates (Costar, Corning, NY) were coated with
0.1g of antigen in phosphate buffered saline (PBS) at 4C
overnight. The plates were washed with PBS containing
0.05% Tween20 (Sigma, St. Louis, MO) (PBST), blocked
with 5% goat serum (Sigma) in PBST at 37C for 1 hr, and
then washed with PBST to remove unbound proteins. Test
sera diluted 1:100 were added to the wells and incubated at
37C for 1 hr. Then the plates were washed with PBST and
incubated with horseradish peroxidase-conjugated, anti-hu-
man IgG or IgM antibodies (Sigma) for another 1 hr. The
bound antibodies were detected following incubation with
100 l of O-phenylene diamine (OPD) substrate (Sigma)
using a microplate reader at 490 nm wavelength. The results
were reported in units of optical density (OD)  standard
deviation (SD). Every anti-Pv200 ELISA experiment includ-
ed at least 3 negative naive individuals and 3 positive patient
samples. Each serum sample was tested at least 3 times,
except in the case of the high numbered seroepidemiologic
survey where only positive samples were reconfirmed. Vir-
tually identical ELISA results were obtained from each sam-
ple tested throughout the study.
DNA template preparation and nested PCR. To detect
blood stage parasites of P. vivax, nested PCR amplification
was applied according to the method of Snounou and oth-
ers.11 To prepare the P. vivax DNA template, frozen whole
blood samples containing EDTA were thawed at room tem-
perature and diluted in 10 volumes of PBS with 0.05% sa-
ponin (Sigma). The parasites were released from erythro-
cytes at room temperature for 30 min and collected by cen-
trifugation (6000  g for 5 min). The supernatant was dis-
carded; the parasite and leukocyte pellet was resuspended in
25 l of PCR buffer without MgCl2; and the mixture was
incubated at 95C for 10 min. The first round of nested PCR
amplification was then performed with a 5 l aliquot of su-
pernatant from this mixture solution. For the first round of
PCR amplification, two Plasmodium genus-specific primers,
rPLU6 (5-TTA AAA TTG TTG CAG TTA AAA CG-3)
and rPLU5 (5-CCT GTT GTT GCC TTA AAC TTC-3)
were used for amplification of small subunit ribosomal RNA
(ssrRNA) genes. The second round of amplification was per-
formed with a 1 l aliquot of product from the first round
of PCR, using species-specific primers of rVIV1 (5-CGC
TTC TAG CTT AAT CCA CAT AAC TGA TAC-3) and
rVIV2 (5-ACT TCC AAG CCG AAG CAA AGA AAG
TCC TTA-3) to produce a P. vivax-specific 120 bp fragment
of ssrRNA genes. All PCR reactions were performed in 2
mM MgCl2, 50 mM KCl, 10 mM TrisCl (pH 8.3), 0.1 mg/
ml gelatin, 125 M of each of the four dNTPs, 250 nM of
each oligonucleotide primer, and 0.4 unit of AmpliTaq poly-
merase (Perkin Elmer Cetus).
RESULTS
Antibody levels in control group and malaria patients.
To determine the cut-off values of anti-Pv200 antibody lev-
els and to evaluate the usefulness of the indirect ELISA
method for anti-Pv200 antigen in diagnosing P. vivax ma-
laria in Korea, anti-Pv200 antibody levels were measured in
sera of 313 normal individuals who had never been exposed
to malaria parasites and 20 patients ill with active malaria.
As shown in Figure 1, mean anti-Pv200 levels of IgG and
IgM isotype antibodies in normal control sera were OD 
SD of 0.08  0.16 and 0.04  0.04, respectively. Based on
these results, OD values of 0.5 and 0.2 (mean  3  SD)
were chosen as the lower limits of positive reactions for IgG
and IgM ELISA results, respectively (these cut-off values
exclude  97% of the control group). Anti-Pv200 antibody
levels of 20 Korean P. vivax malaria patients had mean val-
ues of 1.85  0.29 for the IgG isotype and 1.33  0.29 for
the IgM isotype (Figure 2). All of the patients’ sera were
above the cut-off values, except for one case that was below
the cut-off for IgM.
Changes in antibody levels with a history of malaria.
Serum samples from 8 individual soldiers with recent illness
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FIGURE 2. Anti-Pv200 antibody levels in Plasmodium vivax ma-
laria patients determined by indirect enzyme-linked immunosorbent
assay (ELISA). The thick solid horizontal line and dotted horizontal
line represent the cut-off values of optical densities (OD) in IgG
isotype (0.5) and IgM isotype (0.2) antibodies, respectively. The thin
horizontal lines indicate the mean values of OD in each anti-Pv200
antibody titer.
FIGURE 4. A): Anti-Pv200 antibody levels of serums from 40
soldiers who had served in high-risk Plasmodium vivax malaria ar-
eas and had malaria within 3 months following our sampling. The
horizontal and vertical lines represent the cut-off values of optical
densities (OD) in anti-Pv200 IgG isotype (0.5) and IgM isotype (0.2)
antibodies, respectively. B): Anti-Pv200 antibody levels of serum
from 40 randomly selected soldiers in our sampling pool who had
served in high-risk Plasmodium vivax malaria areas. The horizontal
and vertical lines represent the cut-off values of optical densities in
anti-Pv200 IgG isotype (0.5) and IgM isotype (0.2) antibodies, re-
spectively.
FIGURE 3. Anti-Pv200 antibody levels of 8 individual soldiers
(designated A through H) with a history of Plasmodium vivax ma-
laria determined by indirect enzyme-linked immunosorbent assay
(ELISA). Anti-Pv200 antibody titers of the serum samples from
these 8 soldiers were tested at 4, 6, and 9 months after the malaria
attack.
from P. vivax infection were collected at 4, 6, and 9 months
after recovery following treatment with chloroquine/prima-
quine. The anti-Pv200 IgG antibody levels were sustained
above the limit of positive values for 4 months in all but
one of the soldiers tested, and for 6 months in 3 of the
soldiers tested (Figure 3).
Elevated antibody levels before malaria attack. Ac-
cording to the report by the ROK Armed Forces Medical
Command, 40 of the 1,000 soldiers sampled in May 1997,
had an attack of P. vivax malaria within 3 months after our
sampling. Since these soldiers left the high-risk malarious
area after autumn 1996, we assumed that their illnesses were
caused by infection acquired during the summer of 1996.
Anti-Pv200 antibody levels of these 40 soldiers were com-
pared to the levels of 40 randomly selected soldiers from
the pool of 1,000 (Figure 4). Eleven (27.5%) of the serum
samples were positive for anti-Pv200 IgG and IgM in the 40
soldiers who subsequently experienced a malaria attack,
while only five (12.5%) sera had positive values among the
40 randomly selected soldiers. The value distribution of anti-
Pv200 antibody levels for the remaining 920 soldiers was
virtually identical (12.7% positive for anti-Pv200 IgG and
IgM, data not shown) to that of the 40 randomly selected
soldiers.
Antibody levels in high risk areas. In late January 1998,
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FIGURE 5. Anti-Pv200 antibody levels of 1,713 soldiers who had
been serving in high-risk Plasmodium vivax malaria areas, as deter-
mined by indirect enzyme-linked immunosorbent assay (ELISA).
The horizontal and vertical lines represent the cut-off values of op-
tical densities in anti-Pv200 IgG isotype (0.5) and IgM isotype (0.2)
antibodies, respectively.
FIGURE 6. A): IgG isotype antibody levels against CS protein of
Plasmodium vivax as determined by indirect enzyme-linked immu-
nosorbent assay (ELISA) with V20 (CS capture antigen) in various
groups. Group A: 20 malaria patients; B: 12 soldiers within 6
months after a malaria attack; C: 40 soldiers who had malaria attacks
within 3 months following our sampling; D: 40 soldiers who did not
have a malaria attack within 3 months following our sampling. The
thin horizontal lines indicate the mean optical density (OD) values
in anti-Pv200 IgG antibody titer. B): IgM isotype antibody levels
against CS protein of Plasmodium vivax as determined by indirect
ELISA with V20 (CS capture antigen) in the various groups as
above. The thin horizontal lines indicate the mean OD values in
anti-Pv200 IgM antibody titer.
FIGURE 7. Ethidium bromide-stained 2% agarose gel showing an
example of the amplified Plasmodium vivax ssrRNA gene fragment
by nested polymerase chain reaction (PCR) from the whole blood
samples of soldiers who had served in high-risk Plasmodium vivax
malaria areas. A pool of 1,000 whole-blood samples were tested to
detect the Plasmodium vivax specific ssrRNA gene with 4 samples
identified as positive. Arrow indicates the positive result in samples;
MW  DNA molecular weight marker; normal  result of normal
control whole blood; patient  result of Plasmodium vivax patient
whole blood prior to the drug treatment.
we collected 1,713 serum samples from soldiers who had
been serving since the summer of 1997 in areas with high
malaria transmission rates. Of all the samples tested, 15%
were positive for anti-Pv200 IgG or IgM (Figure 5).
Antibody levels against P. vivax CS protein. Antibody
levels against P. vivax CS protein were tested with V20 an-
tigen in four groups shown in Figure 6: A) 20 malaria pa-
tients; B) 12 soldiers within 6 months after malaria attack;
C) 40 soldiers who had malaria within 3 months after sam-
pling; and D) 40 soldiers who did not have a malaria attack
within 3 months after sampling. The mean IgG antibody titer
of group A patients was 0.40  0.76, which was not signif-
icantly higher than those for the other groups (B, 0.15 
0.37; C, 0.24  0.09; and D, 0.06  0.09) (Figure 6A).
Likewise, the mean IgM antibody level for group A was not
significantly higher (0.37  0.53) compared to those for the
other groups (B, 0.03  0.53; C, OD 0.01  0.02; and D,
0.02  0.02) (Figure 6B).
Detection of P. vivax in blood. Among 1,000 whole blood
samples collected in late May 1997, P. vivax parasites were
detected in 4 soldiers by nested PCR (Figure 7). These sol-
diers had no clinical signs or symptoms of malaria at the
time of our sampling.
DISCUSSION
The present serologic study clearly demonstrated that dis-
tinct anti-Pv200 antibody responses occur in the course of
P. vivax infection experienced during the recent malaria ep-
idemic in the northwestern part of the ROK. There were
clear differences in anti-Pv200 antibody responses between
patient and non-patient groups. These results suggest that
anti-Pv200 antibody detection by ELISA may be useful in
diagnosing Korean P. vivax malaria in suspected patients.
During the course of our study, we demonstrated the exis-
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tence of elevated levels of anti-Pv200 antibodies from sev-
eral suspected patients who had not yet shown P. vivax on
blood film smears, but who later showed positive results of
P. vivax on blood film smears as malaria symptoms pro-
gressed. Further studies using larger sample sizes may be
required to firmly establish the sensitivity and specificity of
the method. One possible confusion in the interpretation of
anti-Pv200 antibody titers is that some individuals may
maintain high anti-Pv200 antibody titers for an extended pe-
riod after recovery from malaria, and even after complete
clearance of the parasite. According to the data from the
prospective longitudinal study of 8 soldiers, most individuals
with Korean P. vivax malaria maintain high anti-Pv200 an-
tibody titers of the IgG isotype for 4 to 6 months after drug
cure (Figure 3). It is possible that some individuals maintain
high anti-Pv200 antibody titers for longer periods. The IgG
isotype of anti-Pv200 antibodies had higher normal back-
ground levels (Figure 1) but a more consistent high response
to infection (Figure 2) than did the IgM isotype. Although
there is a danger of false negatives, the combination of both
IgG and IgM isotype levels against Pv200 antigen could de-
tect Korean patients infected with P. vivax, either in addition
to, or as a replacement for traditional laboratory diagnosis.
One of the intriguing findings in the present study was
that 27.5% of 40 soldiers who later developed symptomatic
malaria had elevated anti-Pv200 antibody levels up to 3
months prior to illness (Figure 4). This implies that the an-
tibody titers against Pv200, or MSP 1 antigen of P. vivax
might have increased in the very early erythrocytic stage of
infection, if not in the hepatic stage. All 40 soldiers were
probably carrying P. vivax during a prolonged incubation
period at the time of our sampling and could have been
infected with P. vivax during the previous summer since all
of the subjects had served in areas of high risk P. vivax
transmission in the summer previous to our sampling, but
were stationed in low-risk P. vivax areas thereafter. In sup-
port of this conclusion, the North Korean (NK) strain of P.
vivax, characteristically, has a long incubation period in
many patients.5 This phenomenon of a long dormancy has
been widely and consistently observed in the course of the
P. vivax malaria outbreak in the ROK.12 According to the
epidemiologic survey conducted by the ROK Armed Forces
Medical Command from 1996 through 1998 (Roh C-S and
others, unpublished data), more than 60% of malaria patients
in the ROK Armed Forces became infected with P. vivax
during the summer of the previous year and became ill
sometime after the winter and spring that followed. During
these prolonged incubation periods of up to 1 year or longer,
no apparent clinical signs and symptoms were observed. On
the other hand, the rest of the malaria patients had short
incubation periods typical of P. vivax malaria in many other
parts of the world. Those malaria patients with a prolonged
incubation period might play a very important role in main-
taining infectious sources of P. vivax malaria for the follow-
ing summer. Hence, the early detection of malaria patients
in a prolonged incubation period could be crucial in trying
to eradicate malaria from Korea. Anti-Pv200 antibody
ELISA could be useful in the early detection of Korean P.
vivax malaria in a certain portion of the population.
Anti-CS antibody levels in the various groups showed a
broad range of values. Since the antibody titers in each group
had diverse distributions, no clear cut-off values could be
defined. CS protein can be classified into two groups ac-
cording to the central 20 nonapeptide repeats: predominant
type I repeats with a GDRADGQPA sequence and variant
type II repeats with an ANGAGNQPG sequence. The use of
different P. vivax CS proteins appears to be regionally bi-
ased.13,14 Therefore, the CS protein of P. vivax in the recent
outbreak of malaria in the ROK is likely to have the se-
quence homologous to the NK strain (predominant type I
repeats). In our results, however, antibody responses against
CS protein with predominant type I repeats appeared to show
no significant differences between patients and other groups
(Figure 6). More than 50% of patients showed markedly
lower anti-CS protein antibody titers (OD 	 0.10). In ad-
dition to the poor antibody responses against CS protein of
P. vivax after a prolonged incubation period, the possibility
that those patients with low antibody titers against CS pro-
tein with type I repeats might have been infected with P.
vivax strain carrying CS protein with variant type II repeats
cannot be excluded.
The survey of 1,713 soldiers in high-risk malaria areas by
anti-Pv200 antibody ELISA demonstrated that at least 10%
of soldiers appeared to have been exposed to the malaria
antigen. This ELISA test could be used in seroepidemiologic
studies as an efficient tool for monitoring malaria prevalence
and incidence in large cohorts.
As a result of the nested PCR of blood samples, we de-
tected 4 soldiers (0.4 %) carrying P. vivax parasites who had
no clinical signs and symptoms associated with P. vivax ma-
laria at the time of our sampling. A few weeks later, 1 of
those 4 soldiers was admitted to the field hospital for P.
vivax malaria. The remaining 3 soldiers were also ordered
to be treated with curative drugs for P. vivax malaria. Al-
though anecdotal, these results indicate that asymptomatic
blood carriers of P. vivax parasites are present in the Korean
population.
The current epidemic of P. vivax malaria in Korea had an
insidious beginning with only a single case detected in
1993.2 The medical community initially suggested that trans-
mission in the ROK was due to mosquitoes flying across the
border from the Democratic People’s Republic of Korea
(DPRK).3 However, although the majority of infection had
occurred in soldiers stationed along the DPRK border, it was
soon apparent that there was extensive transmission in the
ROK civilian community.12,15 Without active surveillance,
some civilian cases will inevitably go undetected because
some people are either asymptomatic or suffer only mild
symptoms. Though parasitemic, these infected people will
not seek treatment and will therefore contribute to expansion
of malaria parasite foci in Korea. Given the extremely long
incubation period of Korean P. vivax in some individuals,1,12
infected people are more likely to travel throughout the pen-
insula before seeking treatment. Extensive geographic move-
ment of the parasite has already occurred in American sol-
diers who carried the infection from Korea to the United
States.1
Since the resurgence of epidemic malaria after a virtual
absence of P. vivax transmission in the ROK for the last 20
years, we have a unique opportunity to study the serology
of Korean P. vivax malaria in young subjects, most of whom
have never experienced the threat of malaria before. To stop
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the current epidemic, a combination of vector control
(Strickman D and others, unpublished data), personal pro-
tection, active case detection, and treatment are likely to be
necessary.4 Considering the challenge of case detection
caused by a long incubation period and the sometimes mild
symptomatology of Korean P. vivax, the anti-Pv200 ELISA
and nested PCR could be valuable tools in a program to
systematically eradicate malaria from the Republic of Korea
once again. These techniques could have been useful in as-
sessing the extent of malarial resurgence earlier in the epi-
demic.
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